Heron Therapeutics is trading at $0.35, up 5.49%, with no fresh company-specific catalyst identified. - Shares fell 10.35% to $0.33 on October 6; the company’s release page lists August 10 as its latest release, not October 7. - Broader markets are sharply lower amid rising Treasury yields, oil and geopolitical concerns ahead of Federal Reserve minutes; the stock’s gain is not explained by that market direction. - No volume information was provided.